

## Drospirenone Containing Oral Contraceptives Drug Use Criteria

Created: October 2014

Reviewed: September 2015, April 2019

Includes:

<b>Yaz©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Yasmin©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Zarah©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Vestura©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Syeda©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Ocella©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Nikki©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Loryna©</b>	<i>Ethinyl Estradiol and Drospirenone</i>
<b>Gianvi©</b>	<i>Ethinyl Estradiol and Drospirenone</i>

\*\*or any other brand or generic formulation of oral contraceptive containing drospirenone.

### **Guideline for Use:**

1. Is the patient being treated for a funded condition by Oregon Health Plan?
  - a. If yes, go to 2
  - b. If no, deny as Below the Funded Line for Oregon Health Plan.
2. Does the patient have Polycystic Ovary Syndrome (PCOS) supported in the chart notes submitted for review?
  - a. If yes, approve for 12 fills.
  - b. If no, go to 3
3. Does the patient have Premenstrual Dysphoric Disorder (PMDD) supported in the chart notes submitted for review?
  - a. If yes, approve for 12 fills.
  - b. If no, deny as not meeting criteria. Please use formulary alternative.

### **Rationale:**

Drospirenone containing oral contraceptives have been associated with an increased risk of thromboembolic events; therefore, in order to ensure the safest and most cost-effective oral contraceptive preparations are utilized for Advanced Health members, the above drug use criteria was developed. Acne must meet Guideline Note 132: Acne Conglobata and Acne Fulminans or Guideline Note 65: Severe Cystic Acne of the Prioritized List of Health Services to be considered a covered comorbid condition.

**FDA Approved Indications:** Indicated for the prevention of pregnancy, treatment of PMDD, and treatment of acne.

Approved by DOCS/WOAH Pharmacy and Therapeutics Committee on 10/27/2014

Approved by Advanced Health Pharmacy and Therapeutics Committee on 4/22/2019, 01/22/2020

**References:**

UpToDate. Ethinyl Estradiol and Drospirenone: Drug Information. October 2014.  
Health Evidence Review Commission Prioritized List of Health Services. Guideline Note 132: Acne Conglobata and Acne Fulminans and Guideline Note 65: Severe Cystic Acne. January 1, 2020 Prioritized List.

Approved by DOCS/WOAH Pharmacy and Therapeutics Committee on 10/27/2014

Approved by Advanced Health Pharmacy and Therapeutics Committee on 4/22/2019, 01/22/2020